{"id":"https://openalex.org/W112442131","doi":"https://doi.org/10.1016/b978-1-4832-8363-0.50194-4","title":"EFFECTS OF DOPAMINE AGONISTS ON DOPAMINERGIC UNIT ACTIVITY","display_name":"EFFECTS OF DOPAMINE AGONISTS ON DOPAMINERGIC UNIT ACTIVITY","publication_year":1979,"publication_date":"1979-01-01","ids":{"openalex":"https://openalex.org/W112442131","doi":"https://doi.org/10.1016/b978-1-4832-8363-0.50194-4","mag":"112442131"},"language":"en","primary_location":{"id":"doi:10.1016/b978-1-4832-8363-0.50194-4","doi":"https://doi.org/10.1016/b978-1-4832-8363-0.50194-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/b978-1-4832-8363-0.50194-4","pdf_url":null,"source":{"id":"https://openalex.org/S4306463230","display_name":"Elsevier eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Catecholamines: Basic and Clinical Frontiers","raw_type":"book-chapter"},"volume":{"id":"https://openalex.org/W4253763218","display_name":"Catecholamines: Basic and Clinical Frontiers"},"type":"book-chapter","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034511392","display_name":"Judith R. Walters","orcid":"https://orcid.org/0000-0002-9192-5222","observed_orcids":["https://orcid.org/0000-0002-9192-5222"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J.R. Walters","raw_affiliation_strings":["Experimental Therapeutics Branch, NINCDS, Bethesda, Md. USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Branch, NINCDS, Bethesda, Md. USA","institution_ids":["https://openalex.org/I1299303238"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075513943","display_name":"Martha D. Baring","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.D. Baring","raw_affiliation_strings":["Experimental Therapeutics Branch, NINCDS, Bethesda, Md. USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Branch, NINCDS, Bethesda, Md. USA","institution_ids":["https://openalex.org/I1299303238"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027101944","display_name":"Joan M. Lakoski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J.M. Lakoski","raw_affiliation_strings":["Experimental Therapeutics Branch, NINCDS, Bethesda, Md. USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Branch, NINCDS, Bethesda, Md. USA","institution_ids":["https://openalex.org/I1299303238"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1299303238"],"apc_list":null,"apc_paid":null,"fwci":1.0024,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.71924747,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":null,"issue":null,"first_page":"637","last_page":"639"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.9429000020027161,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.9429000020027161,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.024700000882148743,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.02449999935925007,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dopamine-agonists","display_name":"dopamine agonists","score":0.9990000128746033},{"id":"https://openalex.org/keywords/apomorphine","display_name":"apomorphine","score":0.8640000224113464},{"id":"https://openalex.org/keywords/lisuride","display_name":"lisuride","score":0.9629999995231628},{"id":"https://openalex.org/keywords/substantia-nigra-pars-compacta","display_name":"substantia nigra pars compacta","score":0.9300000071525574},{"id":"https://openalex.org/keywords/dopaminergic-neurons","display_name":"dopaminergic neurons","score":0.8190000057220459},{"id":"https://openalex.org/keywords/neuronal-activity","display_name":"neuronal activity","score":0.6209999918937683},{"id":"https://openalex.org/keywords/kainic-acid-lesion","display_name":"kainic acid lesion","score":0.8190000057220459},{"id":"https://openalex.org/keywords/striatum","display_name":"striatum","score":0.7720000147819519},{"id":"https://openalex.org/keywords/neurotoxicity","display_name":"neurotoxicity","score":0.4440000057220459}],"concepts":[{"id":"https://openalex.org/C2777525119","wikidata":"https://www.wikidata.org/wiki/Q269111","display_name":"Apomorphine","level":4,"score":0.9468876123428345},{"id":"https://openalex.org/C2777095659","wikidata":"https://www.wikidata.org/wiki/Q424446","display_name":"Lisuride","level":5,"score":0.8482028245925903},{"id":"https://openalex.org/C2780938664","wikidata":"https://www.wikidata.org/wiki/Q753278","display_name":"Substantia nigra","level":4,"score":0.805657148361206},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.7730259895324707},{"id":"https://openalex.org/C2776773494","wikidata":"https://www.wikidata.org/wiki/Q3366041","display_name":"Pars compacta","level":5,"score":0.735852062702179},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.6517028212547302},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5742670297622681},{"id":"https://openalex.org/C2778258207","wikidata":"https://www.wikidata.org/wiki/Q600203","display_name":"Dopamine agonist","level":4,"score":0.570659875869751},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5565605759620667},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5282211303710938},{"id":"https://openalex.org/C2776108384","wikidata":"https://www.wikidata.org/wiki/Q390239","display_name":"Kainic acid","level":4,"score":0.4848693311214447},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.41188502311706543},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4016098976135254},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.3323739171028137},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.26730674505233765},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.1643504500389099},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09343993663787842},{"id":"https://openalex.org/C61174792","wikidata":"https://www.wikidata.org/wiki/Q420510","display_name":"Glutamate receptor","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/b978-1-4832-8363-0.50194-4","doi":"https://doi.org/10.1016/b978-1-4832-8363-0.50194-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/b978-1-4832-8363-0.50194-4","pdf_url":null,"source":{"id":"https://openalex.org/S4306463230","display_name":"Elsevier eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Catecholamines: Basic and Clinical Frontiers","raw_type":"book-chapter"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W1978442412","https://openalex.org/W2004156074","https://openalex.org/W2004259186","https://openalex.org/W2016950113","https://openalex.org/W2021357904","https://openalex.org/W2045367803","https://openalex.org/W2061449934","https://openalex.org/W2132804082","https://openalex.org/W2150650850","https://openalex.org/W2164975184","https://openalex.org/W2401324496"],"related_works":["https://openalex.org/W2067677077","https://openalex.org/W1966577272","https://openalex.org/W2002323655","https://openalex.org/W1996368315","https://openalex.org/W2028373322","https://openalex.org/W2082321459","https://openalex.org/W1968508445","https://openalex.org/W817168277","https://openalex.org/W2070022690","https://openalex.org/W2056288090"],"abstract_inverted_index":null,"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-10T09:11:00.788812","created_date":"2016-06-24T00:00:00"}